Digma Medical
Noninvasive Procedure for Diabetes Treatment
Company Overview
Snapshot
Founded in January 2013 by Irit Yaniv and Ilan Ben-Oren, Digma Medical operates with 11–50 employees. The company has raised $2.36M across 4 funding rounds from 2 investors.
Business overview
Digma Medical is developing a minimally invasive therapy, Endoscopic Glycemic Management (EGM), for type 2 diabetes. This treatment aims to restore the body’s natural ability to control blood glucose levels by targeting the duodenal submucosa, which is central to nutrient sensing and metabolic signaling. The product consists of a console and a single-use catheter compatible with standard gastrointestinal endoscopes, designed for performance in a standard GI endoscopy suite. Digma Medical operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers, hospitals, and doctors.
Log in to access full profile ›Company Intelligence Q&A
- What is Digma Medical's primary focus?
- Digma Medical aims to empower patients and physicians with safe, simple, and effective new therapies for type 2 diabetes, leveraging the power of the duodenum to restore natural blood glucose control.
- What is the Endoscopic Glycemic Management (EGM) therapy?
- The EGM therapy is a minimally invasive treatment developed by Digma Medical that targets the duodenal submucosa to restore the body’s natural ability to control blood glucose levels in patients with type 2 diabetes.
- When was Digma Medical founded?
- Digma Medical was founded in January 2013.
- Who are the founders of Digma Medical?
- Digma Medical was co-founded by Irit Yaniv and Ilan Ben-Oren.
- Which investors have participated in Digma Medical's funding rounds?
- Digma Medical has received investments from Peregrine Ventures and Accelmed across its funding rounds. In May 2022, Peregrine Ventures provided funding to the company.